Current Vaccine Shortages & Delays
This web page contains the latest national information about vaccine supplies and provides guidance to healthcare providers who are facing vaccine shortages or delays.
*Note: Only those vaccines included on the recommended childhood, adolescent, and adult immunization schedules for routine vaccination are included in this update.
National Vaccine Supply Shortages
|Vaccine||Shortage||Temporary Change From Routine Recommendation|
|Diphtheria, Tetanus, & Pertussis (DTaP and Tdap)||No|
|Haemophilus influenzae type B (Hib)||No|
|Hepatitis A||See note 1|
|Hepatitis B||See note 2||2018 Pediatric Hepatitis B Vaccine Supply Update and Guidance Table [4 pages]|
|Human Papillomavirus (HPV)||No|
|Inactivated Polio (IPV)||No|
|Influenza||No||See current information about influenza|
|Measles, Mumps, & Rubella (MMR)||See note 3||See Q&As about monovalent M-M-R vaccines Oct 2009|
|Meningococcal Conjugated (MCV4)||No|
|Pneumococcal Conjugated (PCV)||No|
|Pneumococcal Polysaccharide (PPV)||No|
|Serogroup B Meningococcal (MenB)||No|
|Zoster||See note 4|
Note1: During 2017, large outbreaks of Hepatitis A among adults in several US cities resulted in increased demand for vaccine, resulting in constrained supplies of vaccine. In response, CDC has (1) worked directly with public health officials in affected jurisdictions to provide guidance about targeting vaccine in response to local epidemiology; (2) collaborated with manufacturers to understand options for managing supplies in the private sector and increasing national supply; (3) implemented ordering controls in the public sector; and (4) increased vaccine availability on CDC’s adult vaccine contracts. As available vaccine supplies have increased and progress has been made regarding ongoing outbreaks, the public sector vaccine supply strategy has evolved. In addition, to supporting affected jurisdictions with technical assistance and vaccine supplies, additional vaccine has been made available for unaffected jurisdictions to facilitate routine vaccination activities. Finally, while manufacturers have supply to meet current demand, CDC and vaccine manufacturers continue to monitor ongoing demand for and usage of adult Hepatitis A vaccine closely. Of note, the constraints described in this footnote do not apply to the pediatric Hepatitis A vaccine supply in the US. Updated Mar 2018
Pediatric hepatitis B vaccine: Merck anticipates having a limited supply of pediatric monovalent hepatitis B vaccine through the middle of Q2 2019. GSK has confirmed its ability to continue to address supply gaps for pediatric hepatitis b vaccine during this period, using a combination of monovalent pediatric hepatitis B vaccine and its DTaP-HepB-IPV pediatric combination vaccine (Pediarix). The expected monovalent supply continues to provide sufficient vaccine to cover the hepatitis B birth dose for all children as well as additional pediatric hepatitis B vaccine for second and third doses. However, some adjustments will be needed from providers because of the decrease in monovalent vaccine (see attached guidance in the table above). To ensure an equitable distribution of monovalent hepatitis B vaccine and direct vaccine doses according to CDC’s clinical guidance, CDC has implemented controlled vaccine ordering in the public sector using both Merck’s and GSK’s monovalent pediatric hepatitis B vaccines. In addition, GSK is providing monovalent doses to the private sector market directly and through their channels consistent with CDC’s clinical guidance. GSK’s DTaP-HepB-IPV pediatric combination vaccine (Pediarix) continues to be available in both the public and private sectors.
Adult hepatitis B vaccine: Merck is not currently distributing its adult hepatitis B vaccine and does not expect to be distributing adult hepatitis B vaccine or dialysis formulation throughout the remainder of 2019. GSK and Dynavax have sufficient supplies of adult hepatitis B vaccines to address the anticipated gap in Merck’s supply of adult hepatitis B vaccine during this period; however, preference for a specific presentation (i.e., vial versus syringe) may not be met uniformly during this time. Updated November 2018
Note3: Based on input from the ACIP, professional societies, scientific leaders, and customers on October 26, 2009 Merck announced the company has decided not to resume production of ATTENUVAX® (Measles Virus Vaccine Live), MUMPSVAX® (Mumps Virus Vaccine Live), and MERUVAX®II (Rubella Virus Vaccine Live). This science-based decision will support vaccination of the largest group of appropriate individuals. Updated Jan 2010
Note4: Due to high levels of demand for GSK’s Shingrix vaccine, GSK has implemented order limits and providers have experienced shipping delays. It is anticipated order limits and shipping delays will continue throughout 2019. In response, GSK increased the US supply available for 2018 and plans to make even more doses available in the US in 2019. Additionally, GSK will continue to release doses to all customer types on a consistent and predictable schedule during 2019. Updated November 2018
In the United States shortages of many vaccines in the recommended childhood immunization schedule occurred in the past. Some of these shortages were widespread while others were localized. Reasons for these shortages were multi-factorial and included companies leaving the vaccine market, manufacturing or production problems, and insufficient stockpiles. Consequently, some shortages were only specific to one manufacturer.
Shortages of several of these vaccines necessitated temporary changes in recommendations for their use. During that period, summary information about the shortages including projected duration and recommendations for temporary changes in the childhood immunization schedule were provided.
- Questions including those dealing with changes in child care and school requirements necessitated by vaccine supply problems when they occur can be answered by State Health Department immunization programs.
- General immunization questions can be answered by
The CDC Contact Center at 1-800-CDC-INFO
(1-800-232-4636) English and Español
This vaccines shortages page is updated as needed. If you wish to be notified when it is updated, please use enter your email on this page in the box labeled “Get Email Updates”.
The FDA’s web page on Biological Product Shortages provides additional information regarding regulatory issues related to vaccine supply.
Those acronyms and abbrevations not already spelled out above include
- AAFP – American Academy of Family Physicians
- AAP – American Academy of Pediatrics
- ACIP – Advisory Committee on Immunization Practices
- CDC – Centers for Disease Control and Prevention
- FDA – Food and Drug Administration
- GAO – United States General Accounting Office
- GSK – GlaxoSmithKline
- MMRV – Measles, Mumps, Rubella, and Varicella combination vaccine
- MMWR – Morbidity and Mortality Weekly Report
- NCIRD – National Center for Immunization and Respiratory Diseases
- TTY – teletypewriter
- Other acronyms
- Shortages of travel-related vaccines
- Status of Recently Submitted, Licensed, and Recommended Vaccines & Biologics
Red Book® Online
- Influenza Vaccination Recommendations
- Childhood & Adolescent Immunization Schedules
- Adult Immunization Schedule
- Standards for Immunization Practices for children & adolescents and adults [7 pages]
- Page last reviewed: May 16, 2013
- Page last updated: November 19, 2018
- Content source: